arrow
J

John Corkery

university of hertfordshire
H指数:48
被引数:6,868

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment

非那雄胺和多沙唑嗪相关的抑郁和自杀倾向信号检测:更新的药物警戒证据及全面的精神性评估建议

2026-04-060
OAAI
Possible Eye Disorders in Children Prenatally Exposed to Either Methadone or Buprenorphine in Comparison with Other Medications; An Examination of the Food and Drug Administration (FDA) Pharmacovigilance Database

孕期接触美沙酮或丁丙诺啡的儿童可能出现的眼部疾病与其他药物的对比研究;对食品药品监督管理局(FDA)药物警戒数据库的考察

2026-03-030
OAAI
Reply to comment on: “Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists: an examination of the FAERS database” (Am J Ophthalmol. 2025 Dec 20;S0002-9394(25)00666-X).

回复关于:“接受GLP-1受体激动剂治疗的伴有和不伴有2型糖尿病的人群中潜在眼病的比较:FAERS数据库分析”(Am J Ophthalmol. 2025 Dec 20;S0002-9394(25)00666-X)。

2026-02-100
PRE
Novel psychoactive substances (NPS) as a risk factor for psychosis: a systematic review of the literature

新型精神活性物质(NPS)作为精神病的风险因素:一项文献的系统综述

2025-10-190
OAAI
New trends of drug abuse in custodial settings: A systematic review on the misuse of over-the-counter drugs, prescription-only-medications, and new psychoactive substances

拘留环境中药物滥用的新趋势: 对非处方药,处方药和新型精神活性物质滥用的系统回顾

2024-07-016
OAAI
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis

探索减肥治疗中自杀念头,自我伤害和GLP-1受体激动剂之间的关联: 来自药物警戒措施和揭露分析的见解

2024-05-0113
OAAI